Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?
Status:
Not yet recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The primary objective is to assess if discontinuation of anti- tumor necrosis factor alpha
(TNF) treatment in ulcerative colitis patients in sustained clinical remission, with the
option to restart treatment in the case of relapse, is non-inferior to continued anti-TNF
treatment. Secondary objectives are to assess the efficacy and safety of restarting anti-TNF
treatment after a relapse